Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer
Based on the findings, neoadjuvant immunotherapy for colorectal cancer may be both safe and effective in clinical practice. Furthermore, the study suggested that dual immunotherapy could potentially increase the immunotherapy cycle and contribute to a superior pCR rate. However, the conclusion emphasized the need for further prospective clinical trials to validate these results.
Authors
- Bo Song (ORCID: https://orcid.org/0000-0002-0161-1052)
- Jin Yan (ORCID: https://orcid.org/0000-0002-8488-6034)
- Zijian Deng (ORCID: https://orcid.org/0000-0001-6679-151X)
- Yuanyi Rui
- Yajun Luo
- Tao Pan (ORCID: https://orcid.org/0000-0002-1835-8516)
- Hai Hu (ORCID: https://orcid.org/0000-0001-5345-8371)
- Ke Zhang (ORCID: https://orcid.org/0000-0002-9977-4166)
- Cheng Luo (ORCID: https://orcid.org/0009-0008-2257-6066)
- X. Chen (ORCID: https://orcid.org/0000-0002-6961-7629)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fimmu.2024.1466497
- Citations
- 11
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- National Natural Science Foundation of China